SRTS Stock Overview
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Sensus Healthcare, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.42 |
52 Week High | US$6.55 |
52 Week Low | US$1.79 |
Beta | 0.93 |
1 Month Change | 48.49% |
3 Month Change | 33.50% |
1 Year Change | 103.76% |
3 Year Change | 67.80% |
5 Year Change | 7.54% |
Change since IPO | -7.35% |
Recent News & Updates
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Recent updates
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 11There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital
Oct 17Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger
Jul 04Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop
Mar 14Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?
Mar 06Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger
Oct 11Sensus Healthcare Q2 GAAP EPS, revenue beats
Aug 04Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month
May 21Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts
May 11Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist
Apr 29Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality
Apr 01Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?
Dec 17We Discuss Why Sensus Healthcare, Inc.'s (NASDAQ:SRTS) CEO Compensation May Be Closely Reviewed
May 30Sensus Healthcare: Likely Post-Pandemic Sales Recovery Can Boost Share Price
Apr 26Analysts Expect Breakeven For Sensus Healthcare, Inc. (NASDAQ:SRTS) Before Long
Apr 19Shareholder Returns
SRTS | US Medical Equipment | US Market | |
---|---|---|---|
7D | -11.1% | -0.8% | -0.6% |
1Y | 103.8% | 1.9% | 22.5% |
Return vs Industry: SRTS exceeded the US Medical Equipment industry which returned 1.9% over the past year.
Return vs Market: SRTS exceeded the US Market which returned 22.5% over the past year.
Price Volatility
SRTS volatility | |
---|---|
SRTS Average Weekly Movement | 16.1% |
Medical Equipment Industry Average Movement | 7.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SRTS's share price has been volatile over the past 3 months.
Volatility Over Time: SRTS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 35 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Sensus Healthcare, Inc. Fundamentals Summary
SRTS fundamental statistics | |
---|---|
Market cap | US$88.85m |
Earnings (TTM) | US$4.65m |
Revenue (TTM) | US$31.65m |
19.1x
P/E Ratio2.8x
P/S RatioIs SRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SRTS income statement (TTM) | |
---|---|
Revenue | US$31.65m |
Cost of Revenue | US$12.55m |
Gross Profit | US$19.10m |
Other Expenses | US$14.45m |
Earnings | US$4.65m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.28 |
Gross Margin | 60.34% |
Net Profit Margin | 14.70% |
Debt/Equity Ratio | 0% |
How did SRTS perform over the long term?
See historical performance and comparison